🍽️ thioperamide maleate non-drug

AI Engines For more Details: PerplexityKagi LabsYou

  1. Histamine H3 Receptor Modulation: Thioperamide maleate selectively blocks the histamine H3 receptor, which is involved in the modulation of histamine release and neurotransmitter activity in the brain. By antagonizing these receptors, thioperamide maleate can modulate neurotransmitter release, including histamine, dopamine, serotonin, and norepinephrine, among others.

  2. Neuroscientific Research: Thioperamide maleate is primarily used as a research tool in neuroscience to study the role of histamine H3 receptors in various physiological and pathological processes. Its selective antagonism of these receptors allows researchers to investigate the effects of histamine modulation on neurotransmission, behavior, cognition, and other neurobiological functions.

  3. Cognitive Enhancement: Histamine H3 receptors are known to modulate cognitive function, arousal, and attention. Antagonism of these receptors by compounds like thioperamide maleate has been investigated for its potential cognitive-enhancing effects. Preclinical studies have suggested that histamine H3 receptor antagonists may improve cognitive performance in animal models, raising interest in their potential therapeutic applications for cognitive disorders such as Alzheimer's disease and attention deficit hyperactivity disorder (ADHD).

  4. Wakefulness Promotion: Histamine H3 receptor antagonists have also been studied for their potential wake-promoting effects. By increasing histamine release and neurotransmitter activity in wake-promoting brain regions, thioperamide maleate and other histamine H3 receptor antagonists may have utility in the treatment of sleep disorders such as narcolepsy and excessive daytime sleepiness.

  5. Potential Therapeutic Applications: While thioperamide maleate itself is not used therapeutically in medical practice, its pharmacological effects on histamine H3 receptors have implications for the development of novel treatments for neurological and psychiatric disorders. By understanding the mechanisms of action of thioperamide maleate and related compounds, researchers may identify new drug targets and therapeutic strategies for conditions involving dysregulation of histaminergic neurotransmission.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of thioperamide maleate non-drug On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by thioperamide maleate non-drug

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Blautia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Odoribacter genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Akkermansia genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of thioperamide maleate non-drug on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0.2 -0.2
ADHD 1 0.3 2.33
Age-Related Macular Degeneration and Glaucoma 0.2 0.2
Allergic Rhinitis (Hay Fever) 0.3 0.6 -1
Allergies 2.1 0.1 20
Allergy to milk products 0.1 0.2 -1
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 1 1.6 -0.6
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.7 0.1 6
Ankylosing spondylitis 0.8 0.3 1.67
Anorexia Nervosa 0.6 -0.6
Antiphospholipid syndrome (APS) 0.3 0.1 2
Asthma 0.9 0.3 2
Atherosclerosis 0.4 0.4 0
Atrial fibrillation 0.8 0.3 1.67
Autism 2.1 1.7 0.24
Bipolar Disorder 0.1 0.4 -3
Brain Trauma 0.4 0.2 1
Cancer (General) 0.1 0.9 -8
Carcinoma 1.4 1 0.4
Celiac Disease 0.2 1.4 -6
Cerebral Palsy 0.3 0.5 -0.67
Chronic Fatigue Syndrome 2.3 1.9 0.21
Chronic Kidney Disease 0.8 0.4 1
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.1 -0.1
Chronic Urticaria (Hives) 0.2 -0.2
Coagulation / Micro clot triggering bacteria 0.5 -0.5
Colorectal Cancer 0.6 0.4 0.5
Constipation 0.1 0.5 -4
Coronary artery disease 0.4 0.4 0
COVID-19 4.3 3.7 0.16
Crohn's Disease 1.9 1.4 0.36
cystic fibrosis 0.4 -0.4
deep vein thrombosis 0.1 -0.1
Depression 3.2 2.3 0.39
Dermatomyositis 0.2 -0.2
Eczema 0.2 0.3 -0.5
Endometriosis 0.8 0.1 7
Epilepsy 1 0.8 0.25
Fibromyalgia 1 0.4 1.5
Functional constipation / chronic idiopathic constipation 0.9 0.8 0.13
gallstone disease (gsd) 0.5 0.3 0.67
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 0.7 -6
Generalized anxiety disorder 0.6 0.7 -0.17
Gout 0 0
Graves' disease 0.4 0.7 -0.75
Halitosis 0.1 0.1
Hashimoto's thyroiditis 1.1 0.3 2.67
Hidradenitis Suppurativa 0.1 0.1
hypercholesterolemia (High Cholesterol) 0.1 0.1 0
hyperglycemia 0.8 -0.8
Hyperlipidemia (High Blood Fats) 0.4 0.2 1
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 0.5 1.5 -2
Hypothyroidism 0.9 -0.9
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.8 -0.8
Inflammatory Bowel Disease 1.6 2 -0.25
Insomnia 0.4 0.2 1
Intelligence 0 0
Intracranial aneurysms 0.4 0.2 1
Irritable Bowel Syndrome 0.8 0.5 0.6
Liver Cirrhosis 1.1 0.6 0.83
Long COVID 2.6 3 -0.15
Low bone mineral density 0.1 -0.1
Lung Cancer 0.1 0.5 -4
Mast Cell Issues / mastitis 0.2 -0.2
ME/CFS with IBS 0.1 1.2 -11
ME/CFS without IBS 1.3 0.5 1.6
Menopause 0.5 0.5
Metabolic Syndrome 2.2 2 0.1
Mood Disorders 3.5 2.6 0.35
multiple chemical sensitivity [MCS] 0 0.4 0
Multiple Sclerosis 2.2 0.4 4.5
Multiple system atrophy (MSA) 0.3 0.6 -1
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.4 0.4
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.6 2.2 -2.67
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 2.5 1.4 0.79
obsessive-compulsive disorder 1.1 1.5 -0.36
Osteoarthritis 0.7 0.7
Osteoporosis 0.4 0.5 -0.25
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.9 0.7 0.29
Polycystic ovary syndrome 0.4 0.5 -0.25
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.7 0.7
primary biliary cholangitis 0.1 0.2 -1
Psoriasis 1.2 0.3 3
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.9 0.9 1.11
Rosacea 0.4 0.1 3
Schizophrenia 1.5 0.7 1.14
scoliosis 0 0.1 0
Sjögren syndrome 0.5 0.8 -0.6
Sleep Apnea 0.6 0.9 -0.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 -0.4
Stress / posttraumatic stress disorder 0.5 1.3 -1.6
Systemic Lupus Erythematosus 1.3 0.8 0.63
Tic Disorder 0.1 0.5 -4
Tourette syndrome 0 0.1 0
Type 1 Diabetes 0.7 0.1 6
Type 2 Diabetes 2.2 1.5 0.47
Ulcerative colitis 0.9 0.8 0.13
Unhealthy Ageing 1.2 0.6 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]